34 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Progress in discovery of small-molecule modulators of protein-protein interactions via fragment screening.
Pfizer
Bisphenol A binds to Ras proteins and competes with guanine nucleotide exchange: implications for GTPase-selective antagonists.
Ruhr University Of Bochum
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.
The University Of Arizona
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
Universite£
Targeting KRAS G12D Mutant for the Potential Treatment of Pancreatic Cancer.
Usona Institute
Targeting KRAS Mutant Protein Inhibitor for Potential Treatment in Cancer.
Usona Institute
Dual Inhibition of KRAS G12C and G12D Mutants as a Potential Treatment in Cancer Therapy.
Usona Institute
Small Molecule Inhibitors of KRAS Mutant as a Therapeutic Strategy for the Treatment of Cancer.
Usona Institute
Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS
Shanghai Institute Of Materia Medica (Simm)
De-risking Drug Discovery of Intracellular Targeting Peptides: Screening Strategies to Eliminate False-Positive Hits.
Msd
Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor.
Lilly Research Laboratories
Fragment-to-Lead Medicinal Chemistry Publications in 2019.
Novartis Institutes For Biomedical Research
Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
Jinan University
Chalcones bearing a 3,4,5-trimethoxyphenyl motif are capable of selectively inhibiting oncogenic K-Ras signaling.
Wright State University
Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS
Astrazeneca
Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
China Pharmaceutical University
Inhibitors of KRAS May Potentially Provide Effective Cancer Treatment.
Therachem Research Medilab
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.
Array Biopharma
Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments.
University Of Houston
Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung Cancer.
Pfizer
Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d.
Takeda Pharmaceutical